Invasive lobular carcinoma uncovers mobilized yet dysfunctional immunity driven by tumor-stroma crosstalk and antigen presentation defects
This study reveals that despite high immune infiltration and spatial proximity to cytotoxic T cells, invasive lobular carcinoma exhibits immunotherapy resistance due to defective antigen presentation and an immunosuppressive microenvironment driven by immunoregulatory cancer-associated fibroblasts, suggesting that targeting these fibroblasts could enhance treatment efficacy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Breast cancer is not a single disease but a collection of different conditions, each with its own behavior and response to treatment. Among these, a specific type called invasive lobular carcinoma often presents a puzzle for doctors. Unlike the more common form of breast cancer, which tends to form a distinct lump, this variant spreads through tissue in a single-file line of cells, making it harder to detect and harder to treat with standard therapies. For years, researchers have been trying to unlock the secrets of why immunotherapy, a treatment that trains the body's own immune system to fight cancer, works wonders for some patients but fails for others. The immune system relies on specialized cells, such as T cells, to identify and destroy cancer cells. However, in many cases, these soldiers arrive at the scene but fail to launch an attack, leaving the tumor to grow unchecked. Understanding why this happens in invasive lobular carcinoma is critical, as it affects a significant number of women and currently offers few successful options for immune-based treatments.
A team of researchers at the Institut Paoli-Calmettes in Marseille, France, set out to solve this mystery by looking closely at the microscopic world inside these tumors. They compared the immune environments of invasive lobular carcinoma with those of the more common invasive ductal carcinoma, focusing on patients whose cancers were driven by hormones but did not respond to the HER2 protein. Using a combination of advanced genetic sequencing and detailed imaging, they examined thousands of samples to see exactly which cells were present, where they were located, and what they were doing. Their goal was to understand why the immune system, which seemed to be present in these tumors, was not effectively destroying the cancer.
The researchers discovered a surprising contradiction. When they looked at the number of immune cells in the tumors, they found that invasive lobular carcinoma was actually quite rich in them. In fact, these tumors contained high levels of cytotoxic T cells, the very soldiers designed to kill cancer, as well as organized structures that resemble training camps for the immune system. In many other types of cancer, such a strong presence of immune cells would suggest that the body is fighting back effectively and that immunotherapy would work well. The researchers also found that in these lobular tumors, the cancer cells and the immune cells were physically close to one another, suggesting that the soldiers were right at the front lines, ready to engage.
However, despite this mobilized army, the attack never truly began. The study revealed that while the T cells were present and close to the cancer, they were stuck in a state of dysfunction. They had not fully activated their weapons. Instead of releasing the toxic proteins needed to destroy the tumor, the cells remained in a dormant or improperly trained state. The researchers traced this failure to two main problems. First, the cells responsible for teaching the immune system how to recognize the cancer were not doing their job correctly; they failed to present the necessary signals to wake up the T cells. Second, the environment surrounding the tumor was actively suppressing the immune response. The tissue was filled with a specific type of support cell, known as an inflammatory cancer-associated fibroblast, which creates a chemical barrier that inhibits the immune system. These cells release signals that keep the T cells from becoming fully active, effectively blunting the attack before it can start.
The study also identified specific molecular signals that contribute to this shutdown. The researchers found high levels of a protein called VTCN1, also known as B7-H4, produced by the tumor cells themselves. This protein acts as a brake on the immune system, preventing the T cells from functioning. Unlike other types of cancer where the immune system might become exhausted after a long battle, these T cells in invasive lobular carcinoma never fully started the fight in the first place. They were not worn out; they were simply unable to turn on. This distinction is crucial because it suggests that simply trying to "wake up" the exhausted cells, a strategy that works in other cancers, might not be enough here.
The findings suggest that the failure of immunotherapy in this specific type of breast cancer is not due to a lack of immune cells, but rather a failure of coordination and activation. The immune system is mobilized and present, but it is trapped in a suppressive environment that prevents it from doing its job. The researchers propose that future treatments for these patients should not just focus on the immune cells themselves, but also on the surrounding tissue that is holding them back. By targeting the specific support cells that create the suppressive environment and blocking the inhibitory signals like VTCN1, it may be possible to unlock the potential of the immune system in these patients. This approach offers a new path forward for a group of women who have historically been left behind by standard immunotherapy trials, turning a complex biological puzzle into a clear target for future medical innovation.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.